# A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

> **NCT07471048** · NA · RECRUITING · sponsor: **Sirt3 LLC** · enrollment: 100 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DIETARY_SUPPLEMENT:** Oral supplement containing 200mg Magnolia officinalis bark extract
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT07471048
- **Lead sponsor:** Sirt3 LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471048, "A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07471048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*